IMMU-07. Interim analysis of the HIT-HGG Rez Immunvac study - Dendritic cell vaccination with partial Treg depletion and double checkpoint blockade in children with relapsed high-grade gliomas.

ABSTRACT: Abstract Relapses of high-grade gliomas show an aggressive course and survival 6 months after (sub-)total re-resection was only 62% in former HIT-HGG trials. Immunotherapy by induction of tumor-specific T cells through active immunization might help to control glioma regrowth. In the HIT-HGG-Rez Immunovac trial (Eudra-CT 2013-000419-26) we investigate whether a therapeutic vaccine (autologous dendritic cells loaded with tumor lysate, DCV) combined with Treg-depletion and double checkpoint-inhibition (CI, anti-PD-1/anti-CTLA4) is able to increase the number of patients alive 6 months after relapse. Here, we report interim results after 50% of the intended patients (n=25) have been recruited. 13 children and adolescents (mean age 12.7±4.0 y) with relapsed glioblastomas were screened for the

SUBMITTER:  

PROVIDER: S-EPMC9164642 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature